A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease

The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, activities of daily living, resource utilisation, safety and tolerability, in subjects with mild to moderately severe probable AD.
This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.

Start Date01 Jan 2025

Sponsor / Collaborator

Cerecin, Inc.

NCT05628636 / CompletedPhase 1

A Phase 1, Open-label Study to Evaluate the Tolerability of 21 Days of Treatment With the AC-OLE-01-VA Formulation of Tricaprilin Under Different Dosing Conditions in Healthy Participants

This is an open-label, 3-arm study to compare tolerability of three different titration and dosing schedules of the AC-OLE-01-VA formulation of tricaprilin.
Following a screening of up to 28 days, eligible participants will be initially randomised to one of 2 arms (Arm 1 or Arm 2). Arms 1 and 2 will be completed in advance of Arm 3 with all subsequent participants allocated to Arm 3.

Start Date14 Nov 2022

Sponsor / Collaborator

Cerecin, Inc.

NCT05408780 / CompletedPhase 1

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin, and Matching Placebo to Include Single-dose and Food Effect (Part A), and Titration Tolerability (Part B), in Healthy Subjects

The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.

Start Date14 Jul 2022

Sponsor / Collaborator

Cerecin, Inc.

100 Clinical Results associated with Tricaprylin

100 Translational Medicine associated with Tricaprylin

100 Patents (Medical) associated with Tricaprylin

558

Literatures (Medical) associated with Tricaprylin

01 Feb 2024·Poultry science

Inclusion of trans-cinnamaldehyde and caprylic acid in feed results in detectable concentrations in the chicken gut and reduces foodborne pathogen carriage

Article

Author: Assumpcao, Anna L Facchetti V ; Liyanage, Rohana ; Arsi, Komala ; Donoghue, Annie M ; Jesudhasan, Palmy R R ; Lyte, Joshua M ; Caputi, Valentina

Poultry act as a major reservoir host for Salmonella and Campylobacter spp., the 2 leading causes of foodborne illnesses globally and in the United States. Preharvest stage interventions to reduce foodborne pathogen carriage in poultry are increasingly informed by consumer preference for antibiotic-free poultry production. The in-feed inclusion of plant-derived antimicrobial compounds is a promising antibiotic alternative strategy to reduce foodborne pathogen load in the broiler chicken gut. Yet, the fate of these phytochemicals through the broiler chicken gastrointestinal tract is unknown. Likewise, while in-feed phytochemicals have been widely demonstrated in challenge models to reduce foodborne pathogen carriage, little is known regarding efficacy to curb natural routes of infection. As such, the aim of the present study was 2-fold. We sought to determine the concentrations of 2 phytochemicals, trans-cinnamaldehyde and caprylic acid, in each region of the chicken gastrointestinal tract following their in-feed inclusion over a 6-wk production period. In addition, we investigated how the in-feed provision of these phytochemicals may protect against environmental acquisition of Campylobacter jejuni and Salmonella spp. Trans-cinnamaldehyde and caprylic acid were detected in crop, gizzard, duodenal, jejunal, and ileal contents. Crop and gizzard concentrations were not significantly (P > 0.05) different. A significant (P < 0.05) decrease in phytochemical concentration was observed in intestinal regions compared to crop and gizzard. Trans-cinnamaldehyde was consistently identified in cecal and colon contents, while caprylic acid was not detectable in these regions. Trans-cinnamaldehyde and caprylic acid were found to reduce (P < 0.05) Salmonella load. Together, our data establish that the in-feed addition of trans-cinnamaldehyde and caprylic acid, 2 phytochemicals that have previously been shown to exert antimicrobial activity against poultry-associated foodborne pathogens, results in detectable concentrations in the broiler chicken gastrointestinal tract. By providing researchers with a gastrointestinal region-by-region map of phytochemical concentrations, the present study is expected to inform the choice of in-feed phytochemicals targeting foodborne pathogen carriage in the broiler chicken gastrointestinal tract.

01 Jan 2024·European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Nanostructured lipid carriers loaded into in situ gels for breast cancer local treatment

Article

Author: Lopes, Luciana B ; Martins, Tereza S ; Passos, Julia S ; Ishida, Kelly ; Apolinario, Alexsandra C

In this study, nanostructured lipid carriers (NLC) were developed and employed to obtain in situ thermosensitive formulations for the ductal administration and prolonged retention of drugs as a new strategy for breast cancer local treatment. NLC size was influenced by the type and concentration of the oil phase, surfactants, and drug incorporation, ranging from 221.6 to 467.5 nm. The type of liquid lipid influenced paclitaxel and 5-fluorouracil cytotoxicity, with tributyrin-containing NLC reducing IC₅₀ values by 2.0-7.0-fold compared to tricaprylin NLC in MCF-7, T-47D and MDA-MB-231 cells. In spheroids, the NLCs reduced IC₅₀ compared to either drug solution (3.2-6.2-fold). Although a significant reduction (1.26 points, p < 0.001) on the health index of Galleria mellonella larvae was observed 5 days after NLC administration, survival was not significantly reduced. To produce thermosensitive gels, the NLCs were incorporated in a poloxamer (11 %, w/w) dispersion, which gained viscosity (2-fold) at 37 °C. After 24 h, ∼53 % of paclitaxel and 83 % of 5-fluorouracil were released from the NLC; incorporation in the poloxamer gel further prolonged release. Intraductal administration of NLC-loaded gel increased the permanence of hydrophilic (2.2-3.0-fold) and lipophilic (2.1-2.3-fold) fluorescent markers in the mammary tissue compared to the NLC (as dispersion) and the markers solutions. In conclusion, these results contribute to improving our understanding of nanocarrier design with increased cytotoxicity and prolonged retention for the intraductal route. Tributyrin incorporation increased the cytotoxicity of paclitaxel and 5-fluorouracil in monolayer and spheroids, while NLC incorporation in thermosensitive gels prolonged tissue retention of both hydrophilic and hydrophobic compounds.

01 Dec 2023·Applied nursing research : ANR

Ketogenic therapies in Parkinson's disease, Alzheimer's disease, and mild cognitive impairment: An integrative review

Review

Author: Price, Susan ; Ruppar, Todd M

BACKGROUND:

Ketogenic therapies have shown benefit for seizure reduction in epilepsy but their impact on other neurologic conditions is less known. In this literature review, the efficacy of ketogenic therapies were assessed in Parkinson's disease (PD), Alzheimer's disease (AD), and mild cognitive impairment (MCI).

METHODS:

A literature search was conducted using PubMed, Scopus, and Google Scholar focusing on ketogenic therapies in PD, AD, and MCI.

RESULTS:

A total of 2565 records were identified with a total of 15 studies (3 for PD and 12 for MCI/AD) meeting criteria for analysis. The ketogenic diet was used in all the PD studies and did show significant improvement in motor function either through vocal quality, gait, freezing, tremor, and/or balance. A variety of ketogenic therapies were utilized in the MCI and AD groups including a ketogenic diet, low-carbohydrate diet, modified Adkins diet, Mediterranean diet with coconut oil supplementation, a ketogenic diet with a ketogenic medium chain triglyceride (kMCT) supplement, as well as ketogenic supplements including a ketogenic drink with kMCT, oral ketogenic compounds (Axona and AC-1202), and MCT oil or emulsion. The ketogenic diet independently showed a non-significant trend towards improvement in cognition. The Mediterranean diet, modified Adkins diet, and low-carbohydrate diet showed statistically significant improvements in some, although not all, of their cognitive measures. Use of ketogenic supplements, drinks, or compounds showed variable results in the AD and MCI groups. The Axona and AC-1202 compounds showed no significant improvement in cognition at the end of their respective 90-day trials. Most MCT supplements did show cognitive improvements, although only after 6 months of adherence. Adherence to the intervention was problematic in most of the diet studies.

CONCLUSION:

Ketogenic therapies have promise in PD, AD, and MCI for symptom improvement although larger studies are needed to support their implementation in clinical practice.

News (Medical) associated with Tricaprylin

19 Sep 2023

·www.biospace.com

Cerecin strengthens position in neurometabolism with addition to pipeline

Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and use in positron emission tomography (PET) studies of ketone body metabolism Company expands ketogenic platform following pilot data of CER-0001 in migraine and infantile spasms. CER-022 is a novel diagnostic asset with potential applications in neurology and other therapeutic indications DENVER, Colo. and SINGAPORE, Sept. 19, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the in-license of CER-022 from the University of Alberta. The in-license is part of Cerecin's pipeline expansion and further strengthens its position as a leader in neurometabolism, addressing metabolic targets and bioenergetics in disease. CER-022 could have broad applications in the study of ketone body metabolism and will complement Cerecin's ongoing studies of ketosis in migraine, Alzheimer's disease and infantile spasms epilepsy. CER-022 is an 18Fluorinated beta-hydroxybutyrate ([18F]FBHB) for investigational use in positron emission tomography (PET) studies of ketone body metabolism. PET is an imaging technique using radiolabelled isotopes to measure metabolic activity in cells. CER-022 was developed by Dr. Frank Wuest, Professor of Oncology at the University of Alberta, and colleagues. This month, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for the U.S. Patent Application No. 16/992,940, title: Fluorinated beta-hydroxybutyric acids for PET imaging, licensed to Cerecin by the University of Alberta. 18F radiolabeled 2-deoxyglucose (18FDG) is used in numerous applications relating to the brain, heart and in cancer diagnosis. 18FDG PET has been a transformative diagnostic enabling a better understating of tissue metabolism and the early detection and treatment of diseases, particularly cancers and cardiac function. Similarly, it is hoped that CER-022 will be an important diagnostic tool with broad applications, being of significant value to the Company in future studies of its lead investigational drug compound, CER-0001 (tricaprilin). Commenting on the in-license, Dr Samuel Henderson, Chief Scientific Officer, Cerecin, said, "We are pleased to have in-licensed this technology from the University of Alberta. Radiolabeled glucose has proven to be a valuable tool for the study of many diseases, and with the growing interest in ketone body metabolism, a tool to study ketosis may have similar broad uses. Studies using CER-022 may increase our knowledge of the role of ketosis in a variety of applications." Dr. Frank Wuest, Professor at the University of Alberta said, "Our partnership with Cerecin will advance the study of our molecular imaging technologies and evaluate if CER-022 will be a useful tool for studying ketone body metabolism using PET. Disorders exhibiting altered energy substrate utilization, such as Alzheimer's disease, epilepsy, diabetes, and cancer may be of interest for PET imaging studies using CER-022." About Cerecin Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin's lead compound, CER-0001, is being developed for migraine, Alzheimer's disease and epilepsy. Cerecin's programs leverage its extensive experience in neurology and global drug development. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited (F34.SI), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team and highly innovative programs, Cerecin is becoming a global leader in bioenergetics and neurometabolism. Forward looking statements This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. For more information visit . For further information, please contact: pr@cerecin.com © 2023 Cerecin AC-23-973 View original content to download multimedia: SOURCE Cerecin

License out/in

29 Aug 2023

·www.prnewswire.com

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

Data from the pilot study in infantile spasms showed positive outcomes. The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's partnering discussions. DENVER, Aug. 29, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, today announced that new data on investigational CER-0001 (tricaprilin) in infantile spasms (also known as West syndrome) has been accepted for presentation at the 35th International Epilepsy Congress, held in Dublin, Ireland from September 2nd-6th 2023. The data will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon. The presentation title is, "Treatment of Drug-Resistant Infantile Spasms with CER-0001, A Ketogenic Agent: Preliminary Results". Following the presentation, the materials will be available to view in full at: The trial was an open label pilot study conducted in Australia and Singapore to evaluate the safety and tolerability of CER-0001 for treatment of drug-resistant infantile spasms. Eight patients were enrolled and the dose of CER-0001 was titrated up from 7 to 14 days, followed by a maintenance period of 7 days. CER-0001 was well tolerated in the trial with the most common adverse events being gastrointestinal in nature. As observed on the video electroencephalogram, 50% of subjects enrolled had ≥50% improvement of seizure clusters and 25% of subjects had complete resolution of spasms. The study was registered on clinicaltrials.gov (NCT04727970). Subjects in Australia with a clinical benefit at the end of the maintenance period were allowed to continue in a 1-year open label extension. CER-0001 is an investigational oral small-molecule that is believed to act as a precursor to ketone bodies to increase plasma ketone levels. Many studies have shown that the ketogenic diet may reduce or prevent seizures in children whose seizures could not be controlled by anti-seizure medications. Infantile spasms usually affects children under the age of 36 months and can lead to permanent cognitive, neurologic and sensory problems. The disorder is commonly treated with hormonal medications (such as adrenocorticotropic hormone and prednisolone) and vigabatrin, an anticonvulsant. Both interventions have a burden of monitoring and a significant risk of serious adverse events, hence the need for new therapies that can improve the treatment experience for patients and caregivers. Cerecin's infantile spasms program has received rare paediatric disease designation, orphan drug designation and clearance to study CER-0001 under an Investigational New Drug (IND) from the US FDA, as well as orphan drug designation from the EMA. Dr. Marc Cantillon commented, "We are pleased by our continued progress in developing CER-0001 in epilepsy. This data supports our further investigation of CER-0001 in the treatment of infantile spasms and potentially also in other paediatric seizure disorders where few or no options are available. Planning is already underway for our next study in infantile spasms and other developmental and epileptic encephalopathies". At the International Epilepsy Congress, the Cerecin team will be accompanied by PharmaVentures, a transaction advisory firm, who will be supporting Cerecin's partnering discussions. The Cerecin team will be having meetings with potential partner companies. Infantile spasms Infantile spasms, also known as West Syndrome in other geographies, is a severe, ultra-rare form of epilepsy that affects infants under the age of 36 months. Incidence is estimated at approximately 2,000 new cases in the U.S. per year, which can be classified as an ultra-orphan disease. Infantile spasms patients experience rapid, characteristic muscular contraction or extensions lasting one to two seconds and occurring in clusters ranging from a few spasms to more than 100 spasms per cluster. These epileptic spasms occur along with hypsarrhythmia and developmental stagnation or regression. About Cerecin Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team, Cerecin is becoming a global leader in bioenergetics and neurometabolism. About CER-0001 (tricaprilin) CER-0001 (tricaprilin) is an investigational drug being developed by Cerecin for various neurological indications, including Alzheimer's disease, migraine, and rare epilepsies. CER-0001 is a ketogenic compound and is intended to leverage the numerous activities and benefits of ketone bodies. The safety and efficacy of CER-0001 have not been established. Forward looking statements: This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward- looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. For more information visit . For further information, please contact: [email protected] © 2023 Cerecin AC-23-972 SOURCE Cerecin

Clinical ResultOrphan Drug

09 Aug 2023

·www.prnewswire.com

Celebrate National Wellness Month Gundry MD by Boosting Your Overall Health With MCT Wellness

Gundry MD MCT Wellness Helps Users Maintain High Energy Levels, A Healthy Metabolism, and Mental Sharpness LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- August is National Wellness Month, a time dedicated to prioritizing our well-being and making conscious efforts to improve our overall health. As we focus on enhancing our wellness, incorporating a dietary supplement into our routine can play a key role in helping achieve optimal vitality. Continue Reading Gundry MD MCT Wellness is a revolutionary dietary supplement that delivers MCT (medium-chain triglycerides) to the liver. This groundbreaking dietary supplement also helps maintain a healthy weight, facilitates smoother digestion, and helps enhance mental sharpness. Dr. Steven Gundry, a pioneer in nutrition and a world-renowned heart surgeon, highly recommends incorporating a supplement like Gundry MD™ MCT Wellness into your daily routine. This groundbreaking supplement offers multiple benefits crucial to overall well-being. It can not only aid in maintaining a healthy weight and promoting smoother digestion but can also help enhance mental sharpness. The formula is thoughtfully designed with a potent blend of MCT oil and powerful nutrients, including polyphenols. These components work synergistically to support heightened activity, boost metabolism, and enhance brain health. With its two delightful flavors, watermelon lemonade, and raspberry medley, Gundry MD MCT Wellness is an excellent addition to daily routines, making the pursuit of wellness in honor of National Wellness Month a truly enjoyable and satisfying experience.†* What is Gundry MD MCT Wellness? Gundry MD MCT Wellness is a revolutionary dietary supplement designed to provide your body with MCT (medium-chain triglycerides). These MCTs directly reach the liver and are converted into ketones, which play a crucial role in supporting your brain, mitochondrial health, and metabolism. Gundry MD MCT Wellness stands out with its unique combination of caprylic acid and bioflavonoids. This blend enhances the absorption and utilization of MCTs, leading to higher levels of fat-burning ketones that aid in weight management support. This ground-breaking supplement's bioflavonoids are sourced from grape seed and currant extracts, which expedite the transportation of ketones throughout the body. As a result, users can experience the potent benefits of ketones more rapidly, leading to a noticeable and faster impact on overall well-being. Gundry MD MCT Wellness' potent formula also contains polyphenols, contributing to a healthy and vibrant complexion, helping promote smoother digestion, supporting weight loss efforts, and sustaining energy levels. Overall, Gundry MD MCT Wellness is a powerful and comprehensive supplement that supports various aspects of your health, ensuring you can lead a more vibrant and energetic life.†* What Are The Key Ingredients in Gundry MD MCT Wellness?†* C8 MCT Oil (medium-chain triglycerides) and Acacia Fiber: these ingredients work together to support and maintain your body's ketone levels, ultimately promoting a sustained boost in energy. Bioflavonoids: derived from Grape Seed Extract, Red Currant, and Black Currant, these bioflavonoids play a crucial role in supporting the production of nitric oxide, which facilitates faster transportation of ketones throughout the body, helping ensure a more efficient and effective energy metabolism. The Suggested Use of Gundry MD MCT Wellness To achieve the best possible outcomes, it is advised to blend one scoop of Gundry MD MCT Wellness raspberry medley or watermelon lemonade with 10 ounces of water daily. Enjoy these delightful flavors not only with water but also in various beverages like nut milks, coffee, tea, and more, tailoring it to your personal taste preferences. Whether with or without a meal, the easily digestible formula of Gundry MD MCT Wellness allows for hassle-free consumption. For more detailed information about Gundry MD MCT Wellness, a special informational video is available on the Gundry MD YouTube Page, providing valuable insights into the product's benefits and usage. Where to Purchase Gundry MD MCT Wellness? Gundry MD MCT Wellness Raspberry Medley and Watermelon Lemonade can be purchased on for the price of $79.95 for a 30-day supply with a 90-day purchase price guarantee. About Gundry MD Founded in 2015, Gundry MD is dedicated to providing cutting-edge solutions to its users by using science-backed ingredients that can offer a boost in metabolism, all-day energy, smooth, easy digestion, and a youthful-feeling mind and body. These amazing results all begin with feeding your body powerful health-boosting nutrients like polyphenols. Based on his many years of nutrition research, Dr. Gundry helps create every Gundry MD product. Best-selling Gundry MD products include Total Restore, Energy Renew, and Polyphenol-Rich Olive Oil. All Gundry MD products come with a 90-day purchase price guarantee if you are not satisfied. For more information, visit or @gundrymd on Instagram and Facebook. About Dr. Gundry Founder of Gundry MD, Dr. Steven Gundry is a pioneer in nutrition and one of the world's top cardiothoracic surgeons, as well as medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Beverly Hills, Palm Springs, and Santa Barbara, California. He has spent the past 25 years helping people restore their health by optimizing nutrition and lifestyle choices. Steven Gundry MD is also the host of the health podcast, The Dr. Gundry Podcast, and author of four New York Times best-selling books including The Plant Paradox™ which details his famous lectin-free or Plant Paradox diet. For more information, visit , the Dr. Gundry YouTube channel, @drstevengundry on Instagram, and @drgundry on TikTok. *All individuals are unique. Your results can and will vary. †These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Press contact: Ashley Beenen [email protected] SOURCE Gundry MD

100 Deals associated with Tricaprylin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tricaprylin	N07	DB12176

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	US	-	01 Jan 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 2	US	Cerecin, Inc.	15 Jul 2022
Migraine Disorders	Phase 2	AU	Cerecin, Inc.	17 Dec 2020
Memory Disorders	Phase 2	US	Cerecin, Inc.	01 Jul 2006
Epilepsy	Phase 1	US	Cerecin, Inc.	15 Jul 2022
Spasms, Infantile	Phase 1	AU	Cerecin, Inc.	01 Nov 2021
Spasms, Infantile	Phase 1	SG	Cerecin, Inc.	01 Nov 2021
Taste Disorders	Phase 1	US	Cerecin, Inc.	10 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04437199 (Corporate Publications) Manual	Phase 2	Migraine Disorders	81	Tricaprylin	qjrrlkctva(hzlbojiaje) = For Part 1, there was no meaningful difference in the primary endpoint between treatment arms during Month 3. fuizsrrndr (kauniinprw )	Positive	25 Nov 2022
				Placebo
NCT01741194 (NOURISH AD, Pubmed \| J Alzheimers Dis) Manual	Phase 2/3	Alzheimer Disease	413	AC-1204	crseyowdfl(bibdqqzomw) = zvcrwqnrbw fcowmevfih (arporeyzoh )	Negative	01 Jan 2020
				Placebo	crseyowdfl(bibdqqzomw) = timjfjaseb fcowmevfih (arporeyzoh )
NCT00142805 (Pubmed \| Nutr Metab (Lond))	Phase 2	Alzheimer Disease	152	AC-1202	fvukbmzhcw(fpbnjcwdpx) = qbgguxooqv dszszhjyym (tendehinyr )	Positive	10 Aug 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis